B7-H1 Antibodies

Patent metadata

Field	Value
Publication number	US-8981063-B2
Application number	US-42131009-A
Country	US
Kind code	B2
Filing date	Apr 9, 2009
Priority date	Nov 30, 1999
Publication date	Mar 17, 2015
Grant date	Mar 17, 2015

Abstract

The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.

First claim

What is claimed is:

1. An isolated antibody that binds specifically to a B7-H1 polypeptide which comprises
(a) amino acids having the sequence set forth in SEQ ID NO:1; or
(b) amino acids that are encoded by a polynucleotide comprising nucleotides having the sequence set forth in SEQ ID NO:2.

2. The isolated antibody of claim 1 , which is a monoclonal antibody.

3. The isolated antibody of claim 1 , which binds to the polypeptide comprising amino acids having the sequence set forth in SEQ ID NO:1.

4. An antibody fragment that specifically binds to a B7-H1 polypeptide which comprises
(a) amino acids having the sequence set forth in SEQ ID NO:1; or
(b) amino acids that are encoded by a polynucleotide comprising nucleotides having the sequence set forth in SEQ ID NO:2.

5. The antibody fragment of claim 4 , which is an F(ab) 2 fragment, an Fab fragment or a single-chain Fv fragment (scFv) and which specifically binds to the polypeptide of (a) or (b).

6. The monoclonal antibody of claim 2 , which is a chimeric or a humanized monoclonal antibody.

7. A hybridoma which produces a monoclonal antibody according to claim 2 .

8. The isolated antibody according to claim 1 , which binds to a polypeptide comprising amino acids having a sequence from amino acid residue 23 to amino acid residue 290 of SEQ ID NO:1; or
a polypeptide comprising one or more conservative substitutions in SEQ ID NO:1.

9. The isolated antibody according to claim 1 , which binds to a polypeptide comprising amino acids having a sequence from about amino acid residue 20 to amino acid residue 290 of SEQ ID NO:1.

10. The isolated antibody according to claim 1 , which binds to a polypeptide comprising amino acids having a sequence from amino acid residue 23 to amino acid residue 290 of SEQ ID NO:1.

11. An isolated antibody which selectively binds to a B7-H1 polypeptide which
(a) comprises amino acids having a sequence from amino acid residue 23 to amino acid residue 239 of SEQ ID NO:1.

12. An isolated antibody or an antigen binding fragment thereof which selectively binds to the polypeptide of SEQ ID NO:1.

13. The isolated antibody according to claim 12 which is a polyclonal, a monoclonal, a chimeric, a human, a humanized antibody, or an antigen binding antibody fragment thereof.

14. The isolated antibody according to claim 12 which is an Fab antibody fragment, an F(ab′)2 antibody fragment, a single chain antibody fragment, an scFv antibody fragment, or an antigen-binding fragment thereof.

15. The isolated antibody according to claim 12 which is attached to a solid substrate.

16. The isolated antibody of claim 12 , which inhibits the co-stimulatory activity of said B7-H1 polypeptide of SEQ ID NO:1.

17. The isolated antibody of claim 12 , which inhibits the co-stimulatory activity of said B7-H1 polypeptide of SEQ ID NO:1 on a T-cell.

18. An isolated cell that is capable of expressing the antibody of claim 1 .

19. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable excipient.

20. The composition of claim 19 , wherein said antibody is a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a human antibody, or a humanized antibody.

21. The composition of claim 19 , wherein said antibody inhibits the co-stimulatory activity of said B7-H1 polypeptide of SEQ ID NO:1.

22. A method for detecting the presence of a B7-H1 polypeptide in a sample comprising:
(a) contacting the sample with the isolated antibody of claim 1 ; and
(b) determining the binding of said antibody to the polypeptide in the sample to thereby detect the presence of a B7-H1 polypeptide in the sample.

23. An isolated antibody or an antigen binding fragment thereof which specifically binds to a polypeptide consisting of amino acids having the sequence set forth in SEQ ID NO:1.

24. A method of making an antibody, or an antigen binding fragment thereof comprising:
providing a polypeptide which is (a) a polypeptide comprising amino acids having the sequence set forth in SEQ ID NO:1; or (b) a polypeptide which is encoded by a polynucleotide comprising nucleotides having the sequence set forth in SEQ ID NO:2 to an immunocompetent vertebrate; and
harvesting from the vertebrate blood or serum comprising an antibody which specifically binds to said polypeptide, or an antigen binding fragment thereof.

25. A composition comprising the antibody fragment according to claim 4 and a pharmaceutically acceptable excipient.

26. The composition according to claim 25 , wherein said antibody fragment is an Fab fragment, an F(ab′)2 fragment, a single chain antibody fragment, an scFv antibody fragment, or an antigen-binding fragment thereof.

27. An antibody or an antigen binding fragment thereof which binds to a soluble B7-H1 polypeptide which is not membrane-bound, wherein said soluble B7-H1 polypeptide comprises amino acid domain(s) having the sequence(s) shown in FIG. 2A (SEQ ID NO:1) such that the polypeptide is soluble.

Assignees

• Chen Lieping
• Mayo Foundation

Inventors

• Chen Lieping

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• G01N2333/70532

  B7 molecules, e.g. CD80, CD86 · CPC title

• C07K2317/524

  CH2 domain · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title